Markets
Tech
Media
Success
Video
Markets
Premarkets
Dow
After-Hours
Market Movers
Fear & Greed
World Markets
Investing
Markets Now
Before the Bell
Leading Indicator
Global Energy Challenge
Economy
Energy
Tech
Innovate
Gadget
Mission: Ahead
Upstarts
Business Evolved
Work Transformed
Innovative Cities
Unhackable
Media
Reliable Sources
Success
Boss Files
Fresh Money
Cars
Homes
Biz + Leisure
Center Piece
Perspectives
Video
International
Switzerland
India
Davos
Passion to Portfolio
On: Germany
More
Newsletters
About Us
Accessibility and CC
U.S.
World
Politics
Business
Opinion
Health
Entertainment
Tech
Style
Travel
Sports
Video
Shop
VR
More...
Follow CNN Business
Do Not Sell
Johnson & Johnson
(NYSE:JNJ)
158.55
Delayed Data
As of Dec 05
-0.33
/
-0.21%
Today’s Change
144.95
Today
|||
52-Week Range
181.04
-10.25%
Year-to-Date
Quote
Profile
News
Charts
Forecasts
Financials
Shareholders
Competitors
Latest JNJ News
|
Press Releases
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile US, Caterpillar, Broadcom and Starbucks
4:29am / Zacks.com - Paid Partner Content
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Nov 29 / Zacks.com - Paid Partner Content
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Dec 05 / Zacks.com - Paid Partner Content
2 Unstoppable Dividend Stocks Trading Near 52-Week Lows to Buy Now
Nov 28 / MotleyFool.com - Paid Partner Content
Top Analyst Reports for Johnson & Johnson, T-Mobile & Caterpillar
Dec 05 / Zacks.com - Paid Partner Content
Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?
Nov 27 / Zacks.com - Paid Partner Content
J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag
Dec 05 / Zacks.com - Paid Partner Content
5 Stocks You Can Confidently Invest $500 In Right Now
Nov 27 / MotleyFool.com - Paid Partner Content
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
Dec 04 / Zacks.com - Paid Partner Content
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
Nov 26 / MotleyFool.com - Paid Partner Content
Warren Buffett Just Closed His Position in This Dividend Giant. Should You?
Dec 03 / MotleyFool.com - Paid Partner Content
Johnson & Johnson and Intuitive Surgical Might Become Ozempic's Next Victims. Are They Still Worth Buying?
Nov 26 / MotleyFool.com - Paid Partner Content
Warren Buffett Reduced This Long-Time Berkshire Hathaway Holding by 67%. Should Investors Follow His Lead?
Dec 01 / MotleyFool.com - Paid Partner Content
Warren Buffett-Led Berkshire Hathaway Sells Its Entire Procter & Gamble Stake. Should You?
Nov 25 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
Nov 30 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More
Nov 24 / Zacks.com - Paid Partner Content
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
Nov 29 / Zacks.com - Paid Partner Content
3 Dividend Stocks You Can Safely Hold for Decades
Nov 24 / MotleyFool.com - Paid Partner Content
4 Large Drug Stocks to Watch as IBD Market Gains Traction
Nov 29 / Zacks.com - Paid Partner Content